Pharmaceutical Technology
NOVEMBER 27, 2024
In recent years, the evolution of biologic therapies for severe asthma has paralleled advancements in other chronic conditions such as rheumatoid arthritis and psoriasis, where biologics have also transformed treatment paradigms.
Fierce Pharma
NOVEMBER 8, 2024
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth up to | Alteogen will use its human hyaluronidase hybridization platform to develop a subcutaneous formulation of the blockbuster antibody-drug conjugate.
Pharma IQ
NOVEMBER 28, 2024
Explore strategies for DSCSA compliance with insights from Aladdin Mandishah, Director of Product Marketing at SAP.
European Pharmaceutical Review
NOVEMBER 28, 2024
When the General Data Protection Regulation (GDPR) 1 came into effect in 2018, this appeared to accelerate the migration out of Europe for pharmaceutical clinical trials. This was not so much due to non-compliance but stemmed from regulatory ambiguity. As the EU now sets its sights on the regulation of artificial intelligence (AI) through the EU Artificial Intelligence Act (EU AI Act), 2 similar questions arise regarding the implementation and enforcement of the regulation.
Advertiser: ZoomInfo
Savvy B2B marketers know that a great account-based marketing (ABM) strategy leads to higher ROI and sustainable growth. In this guide, we’ll cover: What makes for a successful ABM strategy? What are the key elements and capabilities of ABM that can make a real difference? How is AI changing workflows and driving functionality? This Martech Intelligence Report on Enterprise Account-Based Marketing examines the state of ABM in 2024 and what to consider when implementing ABM software.
MedCity News
NOVEMBER 24, 2024
Synapticure’s Series A round was led by B Capital and included participation from CommonSpirit Health, CVS Health Ventures and RA Capital. The post Synapticure Secures $25M To Scale Virtual Care for Neurodegenerative Diseases appeared first on MedCity News.
PharmaVoice
NOVEMBER 11, 2024
Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Fierce Pharma
NOVEMBER 14, 2024
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy has already been approved to treat AADC deficiency in Europe and the U.K., among other countries, where it's branded as Upstaza.
pharmaphorum
NOVEMBER 8, 2024
AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities
European Pharmaceutical Review
NOVEMBER 26, 2024
Glucagon-like peptide-1 (GLP-1) receptor agonists have shown to provide meaningful benefits in chronic kidney disease (CKD) and individuals with and without diabetes. This based on the largest, most comprehensive analysis of GLP-1 antagonists on kidney and cardiovascular outcomes. While GLP-1 receptor agonists have shown benefit for type 2 diabetes, obesity and cardiovascular disease, its impact as a treatment in chronic kidney disease is not as clear, the researchers explained.
MedCity News
NOVEMBER 18, 2024
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients. The post Market Trends to Watch for Health Systems and Their Specialty Pharmacies appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
PharmaVoice
NOVEMBER 5, 2024
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
PharmaTech
NOVEMBER 9, 2024
Automation, miniaturization, and new software algorithms are improving throughput and accuracy.
Fierce Pharma
NOVEMBER 1, 2024
An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry. | An FDA investigation last year into the risk of patients developing secondary cancers following the treatment of CAR-T cell therapies sent shock waves across the industry.
pharmaphorum
NOVEMBER 11, 2024
Mass General Brigham researchers have developed an AI that can spot hidden cases of long COVID from electronic health records
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
NOVEMBER 18, 2024
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
MedCity News
NOVEMBER 25, 2024
Endoscopy, the standard for detecting esophageal precancer, is quite an invasive procedure — so a lot of people who should be screened end up never being tested. Lucid Diagnostics is trying to solve this problem by selling a quick, office-based diagnostic. The post This Pill-Size Diagnostic Seeks to Prevent Thousands of Esophageal Cancer Deaths appeared first on MedCity News.
PharmaVoice
NOVEMBER 21, 2024
A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.
European Pharmaceutical Review
NOVEMBER 6, 2024
Dupixent (dupilumab) has been approved by the European Medicines Agency (EMA) as the first treatment for young children with eosinophilic esophagitis in the EU. This authorisation is based on Phase III data which found that 68 percent of children aged one to 11 years given Dupixent (dupilumab) achieved histological disease remission at 16 weeks. This result was maintained for up to one year.
Fierce Pharma
NOVEMBER 20, 2024
Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. | The spinal muscular atrophy drug is a growth driver for the Swiss pharma giant, prompting the company to prioritize its defense against potential generics.
pharmaphorum
NOVEMBER 8, 2024
Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.
Pharmaceutical Technology
NOVEMBER 11, 2024
Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy (REMS) programme.
MedCity News
NOVEMBER 5, 2024
Employers are prioritizing mental wellbeing programs, but employees say they need financial wellbeing support, according to a survey from WTW. The post WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs appeared first on MedCity News.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaVoice
NOVEMBER 8, 2024
Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.
Impetus Digital
NOVEMBER 8, 2024
A version of this article was previously published in the Journal of mHealth. The landscape of publication planning is constantly evolving with the rise of novel digital tools, artificial intelligence, and virtual collaboration platforms. As a result, traditional barriers to effective and efficient publication planning and development are being broken down, while new challenges related to compliance, data security, and global collaboration in the virtual setting have emerged.
Fierce Pharma
NOVEMBER 1, 2024
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semagluti | Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study. The positive results build on the thesis that GLP-1s could become a foundational piece in the treatment paradigm for the fatty liver disease, according to analysts at William Blair.
pharmaphorum
NOVEMBER 4, 2024
Outlook Therapeutics' Lytenava is the first ophthalmic formulation of bevacizumab to be cleared for use by NICE for use in the NHS for wet AMD
Advertiser: ZoomInfo
Over the last two years, there’s been a 76 percent increase in AI adoption across sales organizations. The reason for its rise? AI increases teams’ productivity by predicting and automating actions that require manual effort. In other words, the research that takes reps hours, AI can do in seconds. For sales teams, AI opens up a world of new possibilities, including automating outreach, identifying best-fit buyers, and keeping CRMs flush with fresh data.
Pharmaceutical Technology
NOVEMBER 8, 2024
The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including Ozempic.
MedCity News
NOVEMBER 13, 2024
There has been a surge in digital mental health solutions, making it difficult to know which ones are effective. One Optum exec weighed in on how she’s managing this challenge. The post How One Optum Exec Is Handling the Influx of Digital Mental Health Solutions appeared first on MedCity News.
PharmaVoice
NOVEMBER 19, 2024
AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.
European Pharmaceutical Review
NOVEMBER 21, 2024
In June, the US Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) rejected 1 Lykos Therapeutics’ psychedelic new drug application (NDA) for midomafetamine (MDMA) capsules used alongside MDMA-assisted therapy to treat post-traumatic stress disorder (PTSD) in adults. With the recent failure of Lykos’ trial, how do you see the future of psychedelic therapies in research, especially in treating disorders like depression, PTSD, and substance use diso
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Expert insights. Personalized for you.
98 
Let's personalize your content